Juno Therapeutics, Inc. (JUNO) Shares Bought by TD Asset Management Inc.

TD Asset Management Inc. grew its stake in Juno Therapeutics, Inc. (NASDAQ:JUNO) by 33.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 42,600 shares of the biopharmaceutical company’s stock after purchasing an additional 10,600 shares during the quarter. TD Asset Management Inc.’s holdings in Juno Therapeutics were worth $1,911,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of JUNO. Redmile Group LLC purchased a new position in shares of Juno Therapeutics in the second quarter worth about $66,344,000. Jennison Associates LLC lifted its stake in shares of Juno Therapeutics by 162.0% in the third quarter. Jennison Associates LLC now owns 1,988,708 shares of the biopharmaceutical company’s stock worth $89,213,000 after buying an additional 1,229,622 shares in the last quarter. Wasatch Advisors Inc. purchased a new position in shares of Juno Therapeutics in the second quarter worth about $19,787,000. Marshall Wace North America L.P. purchased a new position in shares of Juno Therapeutics in the second quarter worth about $9,693,000. Finally, Capital World Investors lifted its stake in shares of Juno Therapeutics by 13.8% in the second quarter. Capital World Investors now owns 2,425,000 shares of the biopharmaceutical company’s stock worth $72,483,000 after buying an additional 295,000 shares in the last quarter. 70.37% of the stock is currently owned by hedge funds and other institutional investors.

JUNO has been the topic of several research reports. BTIG Research raised shares of Juno Therapeutics from a “sell” rating to a “neutral” rating in a research note on Monday, August 28th. Zacks Investment Research downgraded shares of Juno Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, August 28th. Wells Fargo & Company reissued an “outperform” rating and issued a $54.00 price target (up from $35.00) on shares of Juno Therapeutics in a research note on Tuesday, September 5th. Barclays initiated coverage on shares of Juno Therapeutics in a research note on Wednesday, September 6th. They issued an “overweight” rating and a $55.00 price target on the stock. Finally, Raymond James Financial raised their price target on shares of Juno Therapeutics from $45.00 to $61.00 and gave the stock an “outperform” rating in a research note on Friday, November 3rd. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $45.48.

In other Juno Therapeutics news, EVP Robert Azelby sold 6,666 shares of Juno Therapeutics stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $54.95, for a total transaction of $366,296.70. Following the transaction, the executive vice president now directly owns 79,998 shares of the company’s stock, valued at $4,395,890.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Sunil Agarwal sold 7,285 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $44.76, for a total transaction of $326,076.60. The disclosure for this sale can be found here. Insiders have sold 54,801 shares of company stock worth $2,527,741 over the last ninety days. 15.08% of the stock is owned by insiders.

Juno Therapeutics, Inc. (JUNO) opened at $58.65 on Monday. The company has a quick ratio of 4.77, a current ratio of 4.77 and a debt-to-equity ratio of 0.01. Juno Therapeutics, Inc. has a 52 week low of $17.52 and a 52 week high of $63.45.

Juno Therapeutics (NASDAQ:JUNO) last issued its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.07. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The company had revenue of $44.80 million for the quarter, compared to the consensus estimate of $18.12 million. During the same period in the previous year, the firm earned ($0.57) earnings per share. Juno Therapeutics’s quarterly revenue was up 115.4% compared to the same quarter last year. sell-side analysts forecast that Juno Therapeutics, Inc. will post -4.02 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3087336/juno-therapeutics-inc-juno-shares-bought-by-td-asset-management-inc.html.

Juno Therapeutics Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Institutional Ownership by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.